Paragon Private Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Paragon Private Wealth Management's VRTX Position: Q2 2026 in Review
Paragon Private Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.9% in Q2 2026, selling an estimated $8.42K and leaving 467 shares worth $232K. The position accounts for 0.06% of the portfolio, ranked #217.
Paragon Private Wealth Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Paragon Private Wealth Management held 467 shares of Vertex Pharmaceuticals worth $232K as of Q2 2026.
- Paragon Private Wealth Management sold 19 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.42K.
- Vertex Pharmaceuticals made up 0.06% of Paragon Private Wealth Management's portfolio in Q2 2026, its #217 holding.
- Paragon Private Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Paragon Private Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.